Different Doses Of Atorvastatin In Patients With Acute Coronary Syndrome The Plasma Sox40l And Hs-crp Levels

Background Current research shows that atherosclerosis is a chronic inflammatory disease, inflammation and immune activation function are the critical pathogenic mechanisim in cardiovascular disease. inflammation reaction determines the mobility of atherosclerotic plaques . T cells in inflammatory immune reaction plays an important role. OX40 and ligand OX40L is the one of important signal pathways activating T-cell. OX40 and ligand OX40L interaction can promot the T cell activation, proliferation and lead to inflammation enlarged , cause the decline of plaques stability, acute coronary syndrome happened. Domestic scholars in recent years in clinical studies also found that patients with acute coronary syndrome in the level of plasma sOX40L significantly higher than normal crowd, and there is a positive correlation among various inflammatory factors such as sOX40L, hs - CRP, P select element.It can serve as a most important inflammatory index in atherosclerosis.Statin has become the first major drug in the treatment of coronary heart disease, there have been many studies confirm that statin reduce the risk of acute cardiovascular events related to its effect on inflammatory biomarkers level reduction. sOX40L is known as new inflammatory index in coronary heart disease, whether statins worked on it, currently rare reports. This study aims to explore whether the statin drugs have influence on new inflammatiory index sOX40L, To investigate the effect of early atorvastatin therapy in different dosages on plasma OX40L and hs-CRP in patients with acute coronary syndrome.Objective To investigate the effect of early atorvastatin therapy in different dosages on plasma sOX40L and hs-CRP in patients with acute coronary syndrome(ACS). Methods plasma concentration of sOX40L and hs-CRP of 60 ACS patients were measured before treatments after admission as well as 20 stable angina pectoris(SA)patients and 20 patients without coronary heart disease as control(C)group. After that,60 ACS patients were divided randomly into two groups,one group treated with 10mg/d atorvastatin as A group, while another treated with 40mg/d atorvastatin as B group.The use of atorvastatin lasted from seven to ten days. plasma sOX40L and hs-CRP concentration were measured again in these patients after treatment.Results1.The plasma concentration of sOX40L and hs-CRP in ACS patients were significantly higher than control group (p<0.05).2. The concentration of sOX40L and hs-CRP after the atorvastatin intervene were decreased in both A and B group. Levels of plasma OX40L in A group are lower , but there is no significantly difference(p>0.05). in B group,which were much lower than before atorvastatin intervene(p<0.05). Levels of plasma hs-CRP had significant decreased in both A and B group. (p<0.05). there were a much stronger sOX40L and hs-CRP decrease in patients taking 40mg/d atorvastatin than in A group(P<0.05).3. And there was a positive correlation between OX40L and hs-CRP in ACS patients(r=0.52,P<0.001).Conclusion The plasma concentration of sOX40L and hs-CRP in ACS patients were significantly higher than control group, The plasma concentration of sOX40L and hs-CRP decreased ofter short term atorvastatin treatment,It is proved in our study that Atorvastatin has a much more significant plasma concentration of sOX40L and hs-CRP decrease at 40mg/d than at 10mg/d. Therefore we suggest that all ACS patients should take atorvastatin at larger dosage as early as possible.